Poor
Misaligned
Patient Risk:
Moderate
Summary
Most claims about sodium excretion/metabolism, CYP3A4 involvement in sodium metabolism, study details, patent/generics, and kidney-monitoring/consultation are not supported by the provided FDA label excerpts. Only the core MOA and some cardiovascular risk endpoints partially align.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting cholesterol production in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase and cholesterol synthesis in the liver; lowers plasma cholesterol/lipoproteins).
Lipitor inhibits the enzyme HMG-CoA reductase.
12.1 Mechanism of Action.
Unsupported Statements
A study found that atorvastatin can increase sodium excretion in the urine.
No provided label sections mention urinary sodium excretion or related studies.
In the study, atorvastatin increased sodium excretion by 15% compared to placebo.
Specific study result not present in provided label excerpts.
The study involved 20 healthy volunteers.
Study design details not present in provided label excerpts.
The results may not be generalizable to patients with kidney disease or other conditions that affect sodium metabolism.
No provided label excerpts discuss generalizability of any sodium-excretion study.
CYP3A4 is involved in the metabolism of sodium.
Provided label excerpts discuss CYP3A4 in atorvastatin metabolism, not sodium metabolism.
A study found that CYP3A4 is responsible for the metabolism of sodium in the kidneys.
Not found in provided label excerpts.
Inhibiting CYP3A4 may increase sodium excretion in the urine.
Not supported by provided label excerpts.
The patent for Lipitor expired in 2011.
No provided label excerpts address patents or market exclusivity.
Generic versions of Lipitor have been developed due to patent expiration.
No provided label excerpts address generics or patent status.
Lipitor may increase sodium excretion in the urine.
Not mentioned in provided label excerpts.
The effect of Lipitor on sodium intake is relatively small.
Not mentioned in provided label excerpts.
The effect of Lipitor on sodium intake may not be clinically significant in most patients.
Not mentioned in provided label excerpts.
Patients with kidney disease or other conditions that affect sodium metabolism should be monitored closely for signs of sodium imbalance.
No provided label excerpts include monitoring guidance for sodium imbalance.
Lipitor (atorvastatin) may actually decrease sodium intake by increasing sodium excretion in the urine.
Not supported by provided label excerpts.
Patients with kidney disease should consult with their healthcare provider before taking Lipitor.
Provided label excerpt states renal disease does not affect plasma concentrations/LDL-C reduction and dose adjustment is not necessary; it does not include a 'consult before taking' instruction.
Contradictions
Important Omissions
Boxed warnings, contraindications, and comprehensive warnings/precautions (beyond provided excerpts) were not provided, limiting assessment of safety alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported sodium-excretion and CYP3A4-sodium mechanistic claims and kidney monitoring/consultation guidance could mislead users, but the provided excerpts do not include any label-supported safety statements about these topics to substantiate risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Multiple substantial claims (sodium excretion/study details, CYP3A4-sodium metabolism, patent/generics, and kidney sodium-imbalance monitoring/consult guidance) are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or replace all sodium-excretion/CYP3A4-sodium/patent-generics and kidney sodium-monitoring/consultation claims with statements directly supported by the provided label sections. Restrict on-label claims to the label-supported MOA and the listed cardiovascular risk-reduction indications.